(NASDAQ: RVMD) Revolution Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.
Revolution Medicines's earnings in 2026 is -$1,131,301,000.On average, 22 Wall Street analysts forecast RVMD's earnings for 2026 to be -$1,480,375,093, with the lowest RVMD earnings forecast at -$1,627,479,206, and the highest RVMD earnings forecast at -$1,061,218,541. On average, 20 Wall Street analysts forecast RVMD's earnings for 2027 to be -$1,283,331,284, with the lowest RVMD earnings forecast at -$1,639,131,801, and the highest RVMD earnings forecast at -$268,425,866.
In 2028, RVMD is forecast to generate -$994,255,750 in earnings, with the lowest earnings forecast at -$1,573,100,425 and the highest earnings forecast at -$226,809,453.